Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
Inclusion Criteria:
- Age >/= 18 years
- Diagnosis of renal cell carcinoma
- Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or
disqulified from therapy with IFN/IL-2
- Patients in whom the oncologist has decide to start therapy with sorafenib.
Exclusion Criteria:
- Synonymous with contraindications to Nexavar.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Study ID:
16268
NCT ID:
NCT01557127
Start Date:
February 2010
Completion Date:
March 2014
Related Keywords:
- Carcinoma, Renal Cell
- Renal cell carcinoma,
- Sorafenib
- Dosing
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
